American Society of Hematology

Fig. 5.

$Fig. 5. OS of the 84 refractory patients according to IPI at relapse and the randomization arm. (A) Patients treated with HDCT versus others among refractory patients. (B) Patients treated with HDCT versus others among refractory patients with an IPI 0-1. (C) Patients treated with HDCT versus others among refractory patients with an IPI 2-3. Of note, the sum of patients in (B) and (C) is not equal to the total number of patients in the new (A), because IPI at relapse was not available in 6 patients for whom information on treatment after failure of DHAP was available (1 received HDCT and 5 received conventional chemotherapy after failure of DHAP).$

OS of the 84 refractory patients according to IPI at relapse and the randomization arm. (A) Patients treated with HDCT versus others among refractory patients. (B) Patients treated with HDCT versus others among refractory patients with an IPI 0-1. (C) Patients treated with HDCT versus others among refractory patients with an IPI 2-3. Of note, the sum of patients in (B) and (C) is not equal to the total number of patients in the new (A), because IPI at relapse was not available in 6 patients for whom information on treatment after failure of DHAP was available (1 received HDCT and 5 received conventional chemotherapy after failure of DHAP).

This Feature Is Available To Subscribers Only